NBTX
NanobiotixNBTX
NBTX
About: Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Employees: 110
0
Funds holding %
of 6,812 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
6.1% less ownership
Funds ownership: 19.72% [Q2] → 13.62% (-6.1%) [Q3]
17% less funds holding
Funds holding: 12 [Q2] → 10 (-2) [Q3]
21% less capital invested
Capital invested by funds: $46.5M [Q2] → $36.9M (-$9.56M) [Q3]
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for NBTX.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
PARIS and CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced a virtual event titled "Accelerating the Future of Nanotherapeutics," scheduled to take place at 9:00 AM ET / 3:00 PM CET on Thursday, December 19, 2024.
Neutral
GlobeNewsWire
2 weeks ago
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
PARIS and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the completion of the dose escalation and dose expansion parts of a Phase 1 study evaluating radiotherapy(“RT”)-activated NBTXR3 (JNJ-1900) for patients with locally advanced pancreatic cancer (“LAPC”) or borderline resectable pancreatic cancer (“BRPC”). The Phase 1 study is being conducted by The University of Texas MD Anderson Cancer Center (“MD Anderson”).
Neutral
GlobeNewsWire
1 month ago
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
PARIS and CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and reported financial results for the third quarter of 2024.
Neutral
GlobeNewsWire
1 month ago
NANOBIOTIX to Participate in Multiple Investor Conferences in November
~ Guggenheim's Inaugural Healthcare Innovation Conference, Nov 11-13 ~ ~ Stifel Healthcare Conference, Nov 18-19 ~ ~ Jefferies London Healthcare Conference, Nov 19-21 ~ PARIS and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences: Guggenheim's Inaugural Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 4pm ET / 10pm CETLocation: Boston, MAPresenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here Stifel Healthcare Conference Date: Monday, November 18, 2024Time: 4:45pm ET / 10:45pm CETLocation: New York, NYPresenter: Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here Jefferies London Healthcare Conference Date: Wednesday, November 20, 2024Time: 1pm GMT / 8am ET / 2pm CETLocation: London, UKPresenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here The fireside chats will be webcast live from the events page of the Investors section of the Company's website.
Neutral
GlobeNewsWire
3 months ago
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
PARIS and CAMBRIDGE, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2024.
Neutral
GlobeNewsWire
3 months ago
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
PARIS and CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the nominations of Dr. Margaret A. Liu and Ms. Anat Naschitz as observers to its Supervisory Board.
Neutral
GlobeNewsWire
3 months ago
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
PARIS and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming H.C. Wainwright 26th Annual Global Investment conference. Please see below for details of the event.
Neutral
GlobeNewsWire
6 months ago
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST.
Neutral
GlobeNewsWire
6 months ago
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
PARIS and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced new data from Study 1100, a US Phase 1 dose escalation and dose expansion study evaluating radiotherapy-activated NBTXR3 followed by anti-PD-1 immune checkpoint inhibitors (“ICIs”) as a second-or-later line (“2L+”) therapy for patients with advanced solid and metastatic tumors. These data were presented by Study 1100 Coordinating Investigator Colette Shen, MD, PhD, at the 2024 Annual Meeting of the American Society for Clinical Oncology (“ASCO 2024”).
Neutral
GlobeNewsWire
7 months ago
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
PARIS and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of updated data from the completed dose escalation part and first data from the ongoing expansion part of Study 1100, a US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) at the 2024 Annual Meeting of the American Society for Clinical Oncology. The data will be presented by Study 1100 Coordinating Investigator Colette Shen, MD, PhD, during a poster presentation session that begins at 10:00 AM EDT / 4:00 PM CEST on Sunday, June 2nd, 2024.
Charts implemented using Lightweight Charts™